2016
Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study
Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L, Group F. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. European Heart Journal Acute Cardiovascular Care 2016, 6: 232-243. PMID: 26787648, DOI: 10.1177/2048872615626656.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionFibrinolytic therapyMyocardial infarctionPercutaneous coronary intervention capabilitySequential cross-sectional studiesChina PEACE-Retrospective AMI StudyPrimary reperfusion strategyPercutaneous coronary interventionLittle clinical evidenceCross-sectional studyQuality of careTwo-stage random samplingCoronary interventionHospital delayNeedle timeReperfusion strategySymptom onsetTherapy useClinical evidenceEmergency departmentMedian admissionIdeal patientPatientsWeighted proportion
2015
Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE‐Retrospective AMI Study
Liu J, Masoudi FA, Spertus JA, Wang Q, Murugiah K, Spatz ES, Li J, Li X, Ross JS, Krumholz HM, Jiang L, Group C. Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From 2001 to 2011: China PEACE‐Retrospective AMI Study. Journal Of The American Heart Association 2015, 4: e001343. PMID: 25713293, PMCID: PMC4345866, DOI: 10.1161/jaha.114.001343.Peer-Reviewed Original ResearchConceptsACEI/ARB therapyAcute myocardial infarctionClass I indicationsARB therapyMyocardial infarctionMortality riskReceptor blockersAngiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor BlockersEnzyme inhibitors/angiotensin receptor blockersChina PEACE-Retrospective AMI StudyChinese AMI patientsClass IIa recommendationRates of therapyAbsence of contraindicationsAngiotensin receptor blockersHigher mortality riskCost-effective therapyIIa recommendationAMI patientsChina PatientRetrospective studyHigh riskPatterns of useChinese guidelinesPatients